RxDoctor Payments Data

Pamela Henderson, MD

Ophthalmology · Hartford, CTNPI 1134122666

Payments from drug & device makers

$1,614in general payments, 2019–2025

Across 56 payments — averaging $28.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$923
  • Johnson & Johnson Surgical Vision, Inc.$289
  • Ivantis, Inc$150
  • Sight Sciences, Inc.$53
  • Oyster Point Pharma, Inc.$50
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$49
  • plus $101 from 3 others

What the payments were for

  • Consulting fees$1509%
  • Food & beverage$1,46491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,614 in reported general payments places this provider in the 60th percentile of 279 ophthalmology providers in Connecticut.

See all ophthalmology providers in Connecticut

Medicare billing

Part B allowed, 2024
$330,453
Medicare patients
812
Services billed
3,452

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost206$129,945
LumiganBimatoprost237$121,730
Brimonidine Tartrate549$85,209
VyzultaLatanoprostene Bunod142$79,939
CombiganBrimonidine Tartrate/Timolol187$77,164
XiidraLifitegrast63$72,153
Alphagan PBrimonidine Tartrate156$53,953
RestasisCyclosporine48$53,721
RhopressaNetarsudil Mesylate93$52,842
SimbrinzaBrinzolamide/Brimonidine Tart141$38,031
Brinzolamide163$29,884
ProlensaBromfenac Sodium63$22,370
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol124$21,361
TafluprostTafluprost/Pf106$19,805
ZioptanTafluprost/Pf48$18,175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P, Restasis$923$306,568628 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$28$182,787299 claims
AlconSimbrinza$27$38,031141 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$49$22,37063 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 279 ophthalmology providers in Connecticut.

Other ophthalmology in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →